Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives
Biologics: Targets and Therapy · 2017
DOI: 10.2147/btt.s108818 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biologics: Targets and Therapy, 2017. Verfasst von Hanford Yau und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Diabetes, and Metabolism, University of California, San Francisco (Fresno Division), Fresno, CA, USA. Die Arbeit wurde bisher 13-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Endocrinology, Diabetes, and Metabolism, University of California, San Francisco (Fresno Division), Fresno, CA, USA.
- Division of Internal Medicine, University of Central Florida College of Medicine, Orlando, FL, USA.
- Division of Endocrinology, Diabetes, and Metabolism, Orlando VA Medical Center, Orlando, FL, USA.
Zitieren
APA
Yau, H., Kinaan, M., Quinn, S. L., & Moraitis, A. G. (2017). Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives. Biologics: Targets and Therapy. https://doi.org/10.2147/btt.s108818
Vancouver
Yau H, Kinaan M, Quinn SL, Moraitis AG. Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives. Biologics: Targets and Therapy. 2017. doi:10.2147/btt.s108818
BibTeX
@article{Yau2017,
author = {Yau, Hanford and Kinaan, Mustafa and Quinn, Suzanne L and Moraitis, Andreas G},
title = {Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives},
journal = {Biologics: Targets and Therapy},
year = {2017},
doi = {10.2147/btt.s108818}
}
EUVIMED